Hot corrosion Type II of FeCr‐based model alloys for boiler and heat exchanger applications

The hot corrosion Type II of the alloys FeCr20, FeCr20Ni10, FeCr20Ni20, and FeCr20Co10 is investigated at 700°C in air + 0.5% SO₂ with deposits consisting of Na₂SO₄ and a eutectic mixture of Na₂SO₄ and MgSO₄ for 24, 100, and 300 h. The alloying elements nickel and cobalt have a positive influence when tests are conducted using a MgSO₄‐Na₂SO₄ deposit. In this case, they reduce the metal loss and increase the time to the propagation stage. In contrast, when the alloys are exposed with a Na₂SO₄ deposit, these alloying elements increase the metal loss and allow for the transition to the propagation stage because they can form molten phases with the Na₂SO₄. During the incubation stage an oxide scale forms on the FeCr20 alloy, which is thicker than the one formed during exposure without a deposit, and iron oxides are observed, which precipitate in the deposit. The propagation stage occurs by a dissolution and precipitation mechanism forming localized pitting attack. Iron is the main species that dissolves and precipitates, while chromium remains mainly as an oxide beneath the initial surface. The additional elements are found in the pit and in the salt deposit.     

Design of novel urogenital pharmabiotic formulations containing lactobacilli,salivaricin CRL 1328 and non-microbial compounds with different functionalities

Context: The administration of pharmabiotics is a promising alternative to antimicrobial drugs for the treatment and/or prevention of female urogenital infections.

Objective: To design pharmabiotic formulations including bioactive ingredients of microbial origin combined with non-microbial substances and then to evaluate the stability of the combinations during freeze-drying and storage.

Materials and methods: Different formulations including Lactobacillus gasseri CRL 1263, Lactobacillus salivarius CRL 1328, salivaricin CRL 1328 (a bacteriocin) and non-microbial compounds (lactose, inulin and ascorbic acid) were assayed, and the ingredients were freeze-dried together or separately. The formulations were stored in gelatin capsules at 4?°C for 360?d.

Results: The viability of lactobacilli was affected to different extents depending on the strains and on the formulations assayed. L. salivarius and ascorbic acid were successfully combined only after the freeze-drying process. Salivaricin activity was not detected in formulations containing L. gasseri. However, when combined with ascorbic acid, lactose, inulin or L. salivarius, the bacteriocin maintained its activity for 360?d. The selected microorganisms proved to be compatible for their inclusion in multi-strain formulations together with lactose, inulin and ascorbic acid. Salivaricin could be included only in a L. salivarius CRL 1328 single-strain formulation together with non-microbial substances.

Conclusions: This study provides new insights into the design of urogenital pharmabiotics combining beneficial lactobacilli, salivaricin CRL 1328 and compounds with different functionalities.